

Myelofibrosis - Epidemiology Forecast - 2032

Market Report | 2022-09-01 | 110 pages | DelveInsight

AVAILABLE LICENSES:

- Single User Price \$3950.00
- Site License Price \$7900.00
- Enterprise Price \$11850.00

Report description:

DelveInsight's 'Myelofibrosis - Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, the EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geographies Covered

- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
- Study Period: 2019-2032

Key Assessments

- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population

Myelofibrosis Understanding

Myelofibrosis Overview

Myelofibrosis is a rare type of blood cancer characterized by the buildup of scar tissue, called "fibrosis," in the bone marrow. The bone marrow cannot make enough healthy blood cells due to increased scar tissue. It is one of the related groups of blood cancers known as "myeloproliferative neoplasms (MPNs)" in which blood cells produced by bone marrow cells develop and function abnormally. When myelofibrosis develops on its own (and not as the result of another bone marrow disease), it is called primary myelofibrosis. In other cases, another type of MPN, such as polycythemia vera (PV) or essential thrombocythemia (ET), can transform into MF. In these cases, it is known as secondary MF, which may also be referred to as a post-PV MF or post-ET MF. Myelofibrosis usually develops slowly, and it often does not cause early symptoms and may be found during a routine blood test. When fibrosis develops in the bone marrow, the bone marrow is unable to produce enough normal blood cells. The lack of blood cells causes many signs and symptoms of myelofibrosis. Several specific gene mutations have been identified in people with myelofibrosis. The most common is the Janus kinase 2 (JAK2) gene mutation, and other less common mutations include CALR and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

MPL. Some people with myelofibrosis do not have any identifiable gene mutations.

Prominent clinical features in myelofibrosis include anemia, hepatosplenomegaly, and constitutional symptoms including fatigue, night sweats, low-grade fever, and progressive cachexia with loss of muscle mass, bone pain, splenic infarct, pruritus, nonhepatosplenic EMH, thrombosis, and bleeding.

Myelofibrosis Diagnosis

Myelofibrosis can be diagnosed by using a series of tests such as blood tests, bone marrow tests, molecular testing, and mutation-enhanced morphologic diagnosis. In order to confirm the diagnosis, the doctor tests the bone marrow. Bone marrow testing involves two steps usually performed at the same time in a doctor's office or a hospital: a bone marrow aspiration removes a liquid marrow sample, and a bone marrow biopsy removes a small amount of bone filled with marrow. Molecular tests are used for diagnosis and treatment planning look for abnormal changes in the genes, chromosomes, proteins, or other molecules within the patient's cancer cells.

Epidemiology Perspective by DelveInsight

The Myelofibrosis epidemiology division provides insights about the historical and current Myelofibrosis patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Myelofibrosis epidemiology [segmented as total prevalent cases, total diagnosed prevalent cases, type-specific cases, based on risk stratification, age-specific cases, based on molecular alterations, treatment eligible pool of myelofibrosis, and transplant eligible/ineligible pool of myelofibrosis] in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Country Wise- Myelofibrosis Epidemiology

? The total prevalent population of myelofibrosis in the 7MM comprised of 39,735 cases in 2021 and is projected to increase during the study period (2019-2032).

? In the United States, the total number of prevalent cases of Myelofibrosis were 19,815 cases in the year 2021 which are expected to grow during the study period, i.e., 2019-2032.

? Among the EU-5 countries, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, followed by the UK, whereas Spain accounted for the lowest cases in 2021.

? The total diagnosed prevalent cases of myelofibrosis in the Japan is 5,391 in 2021 and is projected to increase during the forecast period.

? In the US, based on risk, myelofibrosis cases are stratified in the low risk, intermediate-1 risk, intermediate-2, and high-risk. The high-risk accounted for the highest number of patients in 2021 in the US.

? Myelofibrosis can be further categorized into primary myelofibrosis and secondary myelofibrosis. In 2021, primary myelofibrosis accounted for 75% of all cases in the US.

? In the US, based on age, myelofibrosis cases are stratified in the age group ? 40 years, 41?60 years, and > 60 years. The >60 years accounted for the highest number of patients i.e. 10,275 in 2021 in the US.

? In 2021, treatment eligible pool of myelofibrosis accounted for 9,511 cases in the United States.

? The epidemiology model of myelofibrosis suggests that there are two broad classification based on the molecular enhancement in myelofibrosis, one that includes patients who driver harbor mutations which suggests that highest mutation is observed in JAK2 mutations followed by CALR mutation and MLR mutation. Second category includes patients with triple negative mutations. In the US, JAK2 mutations account for approximately 60% of cases.

? In 2021, transplant ineligible pool of myelofibrosis accounted for 8,980 cases in the United States.

Scope of the Report

- The Myelofibrosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- The Myelofibrosis Report and Model provide an overview of the risk factors and global trends of Myelofibrosis in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom and Japan)
- The report provides insight about the historical and forecasted patient pool of Myelofibrosis in seven major markets covering the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of Myelofibrosis.
- The report provides the segmentation of the Myelofibrosis epidemiology by total prevalent cases, diagnosed prevalent in the 7MM.
- The report provides the segmentation of the Myelofibrosis epidemiology by age-specific, type-specific cases in the 7MM.
- The report provides the segmentation of the Myelofibrosis epidemiology based on the risk stratification and based on molecular alterations in the 7MM.
- The report provides the segmentation of the Myelofibrosis epidemiology by total treated cases and transplant eligible/ineligible cases in the 7MM.

Report Highlights

- 11-Year Forecast of Myelofibrosis epidemiology
- 7MM Coverage
- Total Prevalent Cases of Myelofibrosis
- Total Diagnosed Prevalent Cases of Myelofibrosis
- Total Type-specific Cases of Myelofibrosis
- Total Age-specific Cases of Myelofibrosis
- Myelofibrosis Cases Based on Risk Stratification
- Myelofibrosis Cases Based on molecular alterations
- Total Treated Cases of Myelofibrosis
- Total Transplant Eligible/Ineligible Cases of Myelofibrosis

KOL-Views

We interview KOL's and SMEs ' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

- ? What is the historical Myelofibrosis patient pool in the seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- ? What would be the forecasted patient pool of Myelofibrosis in the 7 major markets covering the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
- ? What will be the growth opportunities in the 7MM concerning the patient population about Myelofibrosis?
- ? Out of all the 7MM countries, which country would have the highest prevalent population of Myelofibrosis during the study period (2019-2032)?
- ? Which mutation and age-group accounts for the highest prevalent population of Myelofibrosis during the study period (2019-2032) and stratification of myelofibrosis patient pool based on the risk.
- ? What is the treatment eligible pool of myelofibrosis in the 7MM and the transplant eligible/ineligible pool of myelofibrosis in the 7MM?
- ? At what CAGR the population is expected to grow in the 7MM during the study period (2019-2032)?
- ? What are the various recent and upcoming events which are expected to improve the diagnosis of Myelofibrosis?

Reasons to buy

The Myelofibrosis Epidemiology report will allow the user to -

- Develop business strategies by understanding the trends shaping and driving the global Myelofibrosis market
- Quantify patient populations in the global Myelofibrosis market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Myelofibrosis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

therapeutics in each of the markets covered

- Understand the magnitude of the Myelofibrosis population by its severity
- The Myelofibrosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
- The Myelofibrosis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources

Table of Contents:

1. Key Insights
2. Report Introduction
3. Myelofibrosis Market Overview at a Glance
 - 3.1. Patient Share (%) Distribution of Myelofibrosis in 2019
 - 3.2. Patient Share (%) Distribution of Myelofibrosis in 2032
4. Executive Summary
5. Epidemiology Methodology
6. Disease Background and Overview
 - 6.1. Introduction
 - 6.2. Subtypes
 - 6.3. Signs and Symptoms
 - 6.4. Causes
 - 6.5. Diagnosis
 - 6.5.1. Blood test
 - 6.5.2. Bone marrow tests
 - 6.5.3. Molecular testing
 - 6.5.4. Mutation-enhanced morphologic diagnosis
 - 6.6. Pathogenesis
 - 6.7. Prognosis
 - 6.8. Risk Factor
7. Risk-based Scoring in Myelofibrosis
8. Epidemiology and Patient Population
 - 8.1. Key Findings
 - 8.2. Assumptions and Rationale
 - 8.3. Total Prevalent Population of Myelofibrosis in the 7MM
 - 8.4. The United States
 - 8.4.1. Total Prevalent Population of Myelofibrosis in the United States
 - 8.4.2. Total Diagnosed prevalent cases of Myelofibrosis in the United States
 - 8.4.3. Type-specific Cases of Myelofibrosis in the United States
 - 8.4.4. Myelofibrosis cases Based on Risk Stratification in the United States
 - 8.4.5. Age-specific Cases of Myelofibrosis in the United States
 - 8.4.6. Myelofibrosis Cases Based on Molecular Alterations in the United States
 - 8.4.7. Treatment Eligible Pool of Myelofibrosis in the United States
 - 8.4.8. Transplant Eligible/Ineligible Pool of Myelofibrosis in the US
 - 8.5. EU-5
 - 8.5.1. Total Prevalent Population of Myelofibrosis in the EU-5
 - 8.5.2. Total Diagnosed Prevalent Cases of Myelofibrosis in the EU-5
 - 8.5.3. Type-specific Cases of Myelofibrosis in the EU-5
 - 8.5.4. Myelofibrosis cases Based on Risk Stratification in the EU-5

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.5. Age-specific Cases of Myelofibrosis in the EU-5
- 8.5.6. Myelofibrosis Cases Based on Molecular Alterations in the EU-5
- 8.5.7. Treatment Eligible Pool of Myelofibrosis cases in the EU-5
- 8.5.8. Transplant Eligible/Ineligible Pool of Myelofibrosis cases in the EU-5
- 8.6. Japan
 - 8.6.1. Total Prevalent Population of Myelofibrosis in Japan
 - 8.6.2. Total Diagnosed Prevalent Cases of Myelofibrosis in Japan
 - 8.6.3. Type-specific Cases of Myelofibrosis in Japan
 - 8.6.4. Myelofibrosis cases Based on Risk Stratification in Japan
 - 8.6.5. Age-specific Cases of Myelofibrosis in Japan
 - 8.6.6. Myelofibrosis Cases Based on Molecular Alterations in Japan
 - 8.6.7. Treatment Eligible Pool of Myelofibrosis in Japan
 - 8.6.8. Transplant Eligible/Ineligible Pool of Myelofibrosis in Japan
- 9. Patient Journey
- 10. Unmet Needs
- 11. Appendix
 - 11.1. Bibliography
 - 11.2. Report Methodology
- 12. DelveInsight Capabilities
- 13. Disclaimer
- 14. About DelveInsight

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Myelofibrosis - Epidemiology Forecast - 2032

Market Report | 2022-09-01 | 110 pages | DelveInsight

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3950.00
	Site License Price	\$7900.00
	Enterprise Price	\$11850.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com